References
Sources & Further Reading
The information on this site is drawn from peer-reviewed research, established harm reduction organizations, and clinical guidelines. Below is an annotated bibliography of key sources along with additional resources for further learning.
Annotated Bibliography
Key research papers and publications that inform our content, with brief explanations of their relevance.
Psychedelic-Assisted Therapy: An Overview for the Internist
Barnett, Brian S., Erin E. Mauney, and Franklin King IV, Cleveland Clinic Journal of Medicine, vol. 92, no. 3, 3 Mar. 2025, pp. 171–180
This clinician-oriented review outlines the structure and rationale of psychedelic-assisted therapy, emphasizing that treatment involves more than drug administration alone. It describes the typical therapeutic model, including patient screening, psychological preparation, a supervised multi-hour dosing session, and post-session integration therapy. The article also reviews emerging evidence for potential benefits across several psychiatric conditions while stressing that regulatory status, clinician training requirements, and safety protocols currently limit widespread clinical implementation.
View sourceExperts Warn of Mental Health Risks after Rise in Magic Mushroom Use
Hall, Rachel, The Guardian, 25 Dec. 2024
This news article reports on growing concerns among mental health professionals regarding adverse outcomes linked to unsupervised psilocybin use. It documents cases of prolonged anxiety, depersonalization, insomnia, and hallucinogen persisting perception disorder, and it notes that many clinicians lack training to identify or treat post-psychedelic distress. The piece contrasts the optimism surrounding clinical trials with the realities of widespread nonclinical use, highlighting how media enthusiasm and online discourse can obscure potential harm.
View sourceHomegrown Trips: Desperate for PTSD Relief, Veterans Turn to Each Other for DIY Psychedelic Treatments
Marshall-Chalmers, Anne, The War Horse, 13 Feb. 2025
This reported feature examines how some veterans engage in peer-led, illegal psychedelic use as a response to perceived failures in conventional PTSD treatment. Through interviews and case narratives, the article describes informal networks that share substances, guidance, and expectations about healing. It also addresses the legal, psychological, and medical risks associated with do-it-yourself treatment models. By focusing on veterans' motivations and constraints, the piece illustrates why individuals may pursue psychedelics despite legal barriers and limited clinical oversight.
View sourceSpecial Considerations for Evaluating Psilocybin-Facilitated Psychotherapy in Vulnerable Populations
Ortiz, Cynthia E., et al., Neuropharmacology, vol. 214, 15 Aug. 2022, article 109127. Elsevier
This scholarly review argues that vulnerable and historically marginalized populations are often excluded from psilocybin clinical trials, despite experiencing disproportionate mental health burdens. The authors examine how conventional study designs can fail to account for cultural context, historical trauma, and differences in risk exposure. The article outlines ethical and methodological considerations for inclusive research, including recruitment practices, informed consent, outcome measurement, and therapist cultural competence. It frames equity as essential not only for ethics but also for the scientific validity of psychedelic research.
View sourceInterview by Parthiv Mothipati
Ortiz, Cynthia E., 18 Nov. 2025. Google Meet
This primary-source interview provides insight into how psychedelic clinical trials are structured in practice, including preparation, supervised dosing, and post-session integration. It discusses the difficulty regulators face in evaluating the therapeutic framework that surrounds psychedelic use, as opposed to evaluating the drug alone. The interview also addresses how historical mistrust, representation, and community engagement influence participation in research and perceptions of legitimacy.
Ethical and Legal Issues in Psychedelic Harm Reduction and Integration Therapy
Pilecki, Brian, et al., Harm Reduction Journal, vol. 18, no. 1, 7 Apr. 2021, article 40. Springer Nature
This article explores the ethical and legal challenges faced by clinicians who offer preparation or integration support in contexts where psychedelic use remains illegal. It distinguishes harm reduction practices from facilitating access to controlled substances and examines issues such as professional boundaries, documentation, and liability. The authors argue that rising public interest in psychedelics has outpaced legal and clinical infrastructure, creating gray areas for mental health providers.
View source